glp 1 constant diarrhea Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide Receptor Agonist Liraglutide Managing Diarrhea on GLP-1 Medications

The landmark FLOW trial , published in the New England Journal of Medicine in 2024, demonstrated that semaglutide reduced the risk of major kidney disease events by 24% in patients with type 2 diabetes and chronic kidney disease (hazard ratio 0.76

Allouche-Fitoussi D, Breitbart H

Most providers follow the same FDA-based baseline: Obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, prediabetes, dyslipidemia, or obstructive sleep apnea

Unmanaged stress can counteract all those other healthy things you are doing for yourself, so getting ahead of the curve is important